Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIMERVAX as Heterologous Booster in Adolescents
NCT06234956Phase 2Completed
- Sponsor
- HIPRA
- Start
- Jun 2023
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PHH-1V in coronavirus disease 2019 (COVID-19), sponsored by HIPRA. Primary endpoints: Changes in immunogenicity against Omicron BA.1 at 14 days, Incidence of solicited local and systemic reactions at 7 days and 5 more. Started Jun 2023; status: completed.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06234956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234956.